Atara Biotherapeutics, Inc. (ATRA) News

Atara Biotherapeutics, Inc. (ATRA): $14.86

0.60 (+4.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

Filter ATRA News Items

ATRA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ATRA News Highlights

  • ATRA's 30 day story count now stands at 11.
  • Over the past 22 days, the trend for ATRA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • VRTX, DECK and MS are the most mentioned tickers in articles about ATRA.

Latest ATRA News From Around the Web

Below are the latest news stories about Atara Biotherapeutics Inc that investors may wish to consider to help them evaluate ATRA as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Atara Biotherapeutics (ATRA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTX – Research Report) and Atara Biotherapeutics (ATRA – Research Report). Vertex Pharmaceuticals (VRTX) Needham analyst Joseph Stringer maintained a Hold rating on Vertex Pharmaceuticals today. The company's shares closed last Wednesday at $226.58. According to TipRanks.

Howard Kim on TipRanks | January 27, 2022

Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm

SOUTH SAN FRANCISCO, Calif., January 26, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Atara’s T-Cell Operations and Manufa

Yahoo | January 26, 2022

New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif., January 24, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today lauded the second high impact study this month solidifying EBV as the primary driver of the development of MS. The paper, titled, "Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM," w

Yahoo | January 24, 2022

Atara Biotherapeutics (ATRA) Investor Presentation (Slideshow)

The following slide deck was published by Atara Biotherapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 14, 2022

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., January 10, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Company’s 2021 accomplishments across strategic priorities and key upcoming catalysts at the 40th Annual J.P. Morgan He

Yahoo | January 10, 2022

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., January 07, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 57,164 restricted stock units of Atara’s common stock to 12 newly hired employees and stock options to purchase an aggregate of 64,925 shares of Atara’s common stock to seven such newly hired e

Yahoo | January 7, 2022

Atara extends partnership with Be The Match BioTherapies for donor cells

Atara Biotherapeutics (ATRA +2.9%) announced a multi-year extension for its collaboration with Be The Match BioTherapies to source healthy donor cells for the off-the-shelf T-cell immunotherapy platform of the company. From 2016, Be The Match was a strategic supplier for Atara (NASDAQ:ATRA) delivering cellular starting material, peripheral blood mononuclear cells...

Seeking Alpha | January 6, 2022

Atara extends partnership with Be The Match BioTherapies for donor cells (NASDAQ:ATRA)

Atara Biotherapeutics <> announced a multi-year extension for its collaboration with Be The Match BioTherapies to source healthy donor cells for the off-the-shelf T-cell

Seeking Alpha | January 6, 2022

Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension

MINNEAPOLIS & SOUTH SAN FRANCISCO, Calif., January 06, 2022--Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension

Yahoo | January 6, 2022

Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., January 05, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM PST / 5:15 PM E

Yahoo | January 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 3.2428 seconds.